Experimental parathyroid hormone gene therapy using ØC31 integrase

Sihoon Lee, Soon Won Hong, Han Seok Choi, Lee Young Lee, Chunja Nam, Yumie Rhee, Ung Il Chung, Sung Kil Lim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

ØC31 integrase can integrate targeted plasmid DNA into preferred locations in mammalian genomes, resulting in robust, long-term expression of the integrated transgene. This system represents an effective tool that opens up promising possibilities for gene therapy. The classical treatment for hypoparathyroidism was calcium and vitamin D replacement. Recently, parathyroid hormone (PTH) replacement was reported to be a more potentially physiologic treatment option. However, PTH synthesis is technically difficult and costly. These issues may be minimized by using PTH gene therapy. We attempted to achieve site-specific genomic integration of the PTH gene into a human cell line and mice using this system. We cotransfected 293 HEK cells with PTH-attB plasmid with or without ØC31 integrase plasmid. Expression and secretion of PTH into culture supernatants and site-specific genomic integration of PTH cDNA were assessed by immunoradiometric assays and pseudo-site analysis, respectively. In in vivo experiments, we injected the PTH-attB plasmid with or without ØC31 integrase plasmid into a mouse tail vein using the hydrodynamic method. Plasma PTH concentrations were serially measured, and site-specific integration of PTH cDNA into the mouse genome was confirmed by examining hepatic genomic DNA. PTH was expressed and secreted from 293 HEK cells and mouse hepatocytes, and pseudo-site analysis confirmed the site-specific integration of PTH cDNA into the host genomes. The site-specificity and efficiency of this system are advantageous in many areas, including, potentially, gene therapy. PTH gene therapy is one candidate; however, for clinical applications, we need to regulate PTH expression and secretion in the future.

Original languageEnglish
Pages (from-to)1033-1041
Number of pages9
JournalEndocrine Journal
Volume55
Issue number6
DOIs
Publication statusPublished - 2008 Dec 1

Fingerprint

Integrases
Parathyroid Hormone
Genetic Therapy
Plasmids
Complementary DNA
HEK293 Cells
Genome
Immunoradiometric Assay
Hypoparathyroidism
DNA
Hydrodynamics
Transgenes
Vitamin D

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Lee, Sihoon ; Hong, Soon Won ; Choi, Han Seok ; Lee, Lee Young ; Nam, Chunja ; Rhee, Yumie ; Chung, Ung Il ; Lim, Sung Kil. / Experimental parathyroid hormone gene therapy using ØC31 integrase. In: Endocrine Journal. 2008 ; Vol. 55, No. 6. pp. 1033-1041.
@article{fc4cd8222d124e7ab19799000de3ab38,
title = "Experimental parathyroid hormone gene therapy using {\O}C31 integrase",
abstract = "{\O}C31 integrase can integrate targeted plasmid DNA into preferred locations in mammalian genomes, resulting in robust, long-term expression of the integrated transgene. This system represents an effective tool that opens up promising possibilities for gene therapy. The classical treatment for hypoparathyroidism was calcium and vitamin D replacement. Recently, parathyroid hormone (PTH) replacement was reported to be a more potentially physiologic treatment option. However, PTH synthesis is technically difficult and costly. These issues may be minimized by using PTH gene therapy. We attempted to achieve site-specific genomic integration of the PTH gene into a human cell line and mice using this system. We cotransfected 293 HEK cells with PTH-attB plasmid with or without {\O}C31 integrase plasmid. Expression and secretion of PTH into culture supernatants and site-specific genomic integration of PTH cDNA were assessed by immunoradiometric assays and pseudo-site analysis, respectively. In in vivo experiments, we injected the PTH-attB plasmid with or without {\O}C31 integrase plasmid into a mouse tail vein using the hydrodynamic method. Plasma PTH concentrations were serially measured, and site-specific integration of PTH cDNA into the mouse genome was confirmed by examining hepatic genomic DNA. PTH was expressed and secreted from 293 HEK cells and mouse hepatocytes, and pseudo-site analysis confirmed the site-specific integration of PTH cDNA into the host genomes. The site-specificity and efficiency of this system are advantageous in many areas, including, potentially, gene therapy. PTH gene therapy is one candidate; however, for clinical applications, we need to regulate PTH expression and secretion in the future.",
author = "Sihoon Lee and Hong, {Soon Won} and Choi, {Han Seok} and Lee, {Lee Young} and Chunja Nam and Yumie Rhee and Chung, {Ung Il} and Lim, {Sung Kil}",
year = "2008",
month = "12",
day = "1",
doi = "10.1507/endocrj.K08E-040",
language = "English",
volume = "55",
pages = "1033--1041",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "6",

}

Lee, S, Hong, SW, Choi, HS, Lee, LY, Nam, C, Rhee, Y, Chung, UI & Lim, SK 2008, 'Experimental parathyroid hormone gene therapy using ØC31 integrase', Endocrine Journal, vol. 55, no. 6, pp. 1033-1041. https://doi.org/10.1507/endocrj.K08E-040

Experimental parathyroid hormone gene therapy using ØC31 integrase. / Lee, Sihoon; Hong, Soon Won; Choi, Han Seok; Lee, Lee Young; Nam, Chunja; Rhee, Yumie; Chung, Ung Il; Lim, Sung Kil.

In: Endocrine Journal, Vol. 55, No. 6, 01.12.2008, p. 1033-1041.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Experimental parathyroid hormone gene therapy using ØC31 integrase

AU - Lee, Sihoon

AU - Hong, Soon Won

AU - Choi, Han Seok

AU - Lee, Lee Young

AU - Nam, Chunja

AU - Rhee, Yumie

AU - Chung, Ung Il

AU - Lim, Sung Kil

PY - 2008/12/1

Y1 - 2008/12/1

N2 - ØC31 integrase can integrate targeted plasmid DNA into preferred locations in mammalian genomes, resulting in robust, long-term expression of the integrated transgene. This system represents an effective tool that opens up promising possibilities for gene therapy. The classical treatment for hypoparathyroidism was calcium and vitamin D replacement. Recently, parathyroid hormone (PTH) replacement was reported to be a more potentially physiologic treatment option. However, PTH synthesis is technically difficult and costly. These issues may be minimized by using PTH gene therapy. We attempted to achieve site-specific genomic integration of the PTH gene into a human cell line and mice using this system. We cotransfected 293 HEK cells with PTH-attB plasmid with or without ØC31 integrase plasmid. Expression and secretion of PTH into culture supernatants and site-specific genomic integration of PTH cDNA were assessed by immunoradiometric assays and pseudo-site analysis, respectively. In in vivo experiments, we injected the PTH-attB plasmid with or without ØC31 integrase plasmid into a mouse tail vein using the hydrodynamic method. Plasma PTH concentrations were serially measured, and site-specific integration of PTH cDNA into the mouse genome was confirmed by examining hepatic genomic DNA. PTH was expressed and secreted from 293 HEK cells and mouse hepatocytes, and pseudo-site analysis confirmed the site-specific integration of PTH cDNA into the host genomes. The site-specificity and efficiency of this system are advantageous in many areas, including, potentially, gene therapy. PTH gene therapy is one candidate; however, for clinical applications, we need to regulate PTH expression and secretion in the future.

AB - ØC31 integrase can integrate targeted plasmid DNA into preferred locations in mammalian genomes, resulting in robust, long-term expression of the integrated transgene. This system represents an effective tool that opens up promising possibilities for gene therapy. The classical treatment for hypoparathyroidism was calcium and vitamin D replacement. Recently, parathyroid hormone (PTH) replacement was reported to be a more potentially physiologic treatment option. However, PTH synthesis is technically difficult and costly. These issues may be minimized by using PTH gene therapy. We attempted to achieve site-specific genomic integration of the PTH gene into a human cell line and mice using this system. We cotransfected 293 HEK cells with PTH-attB plasmid with or without ØC31 integrase plasmid. Expression and secretion of PTH into culture supernatants and site-specific genomic integration of PTH cDNA were assessed by immunoradiometric assays and pseudo-site analysis, respectively. In in vivo experiments, we injected the PTH-attB plasmid with or without ØC31 integrase plasmid into a mouse tail vein using the hydrodynamic method. Plasma PTH concentrations were serially measured, and site-specific integration of PTH cDNA into the mouse genome was confirmed by examining hepatic genomic DNA. PTH was expressed and secreted from 293 HEK cells and mouse hepatocytes, and pseudo-site analysis confirmed the site-specific integration of PTH cDNA into the host genomes. The site-specificity and efficiency of this system are advantageous in many areas, including, potentially, gene therapy. PTH gene therapy is one candidate; however, for clinical applications, we need to regulate PTH expression and secretion in the future.

UR - http://www.scopus.com/inward/record.url?scp=58549090319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58549090319&partnerID=8YFLogxK

U2 - 10.1507/endocrj.K08E-040

DO - 10.1507/endocrj.K08E-040

M3 - Article

C2 - 18689953

AN - SCOPUS:58549090319

VL - 55

SP - 1033

EP - 1041

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 6

ER -